Avecho meets TGA ahead of Phase III Clinical Trial
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Avecho Biotechnology Limited has announced that it met with the Australian Therapeutic Goods Administration to discuss its Phase III clinical trial design for insomnia treatment. The TGA confirmed that no changes are needed to the trial design, allowing Avecho to proceed with patient recruitment as planned. Avecho aims to be the first company to gain regulatory approval for a Phase III cannabidiol trial in Australia with its oral CBD soft-gel capsule.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- AVE receives final ethics approval for Phase III CBD trial
- Appendix 4E and Annual Report 31 December 2023
- December 2023 Quarterly Activities Report & Appendix 4C
- September 2023 Quarterly Activities Report & Appendix 4C
- Reinstatement to Official Quotation
Later from Avecho Biotechnology
- Avecho commences Phase III insomnia trial
- March 2024 Quarterly Activities Report & Appendix 4C
- First Patient dosed in Phase III insomnia trial
- Chair's Address and CEO Presentation
- June 2024 Quarterly Activities Report & Appendix 4C
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology